Live feed07:00:00·1244dPRReleasevia QuantisnowSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 MillionByQuantisnow·Wall Street's wire, on your screen.SLGL· Sol-Gel Technologies Ltd.Health Care
